Tag: Myers
Bristol Myers: supply contract with Cellares
(CercleFinance.com) – Bristol Myers Squibb announces that it has signed a global capacity reservation and supply agreement with Cellares for the manufacturing of CAR-T cell therapies, in a transaction valued…
Bristol Myers: New data on schizophrenia
(CercleFinance.com) – Bristol Myers Squibb presents new interim pooled safety and long-term metabolic outcomes data from the EMERGENT program evaluating KarXT in schizophrenia at the 2024 Annual Meeting of the…
Bristol Myers: success of the takeover bid for RayzeBio
(CercleFinance.com) – Bristol Myers Squibb announces the success of its takeover bid (OPA) for RayzeBio shares, for a purchase price of $62.50 per share, or approximately $4.1 billion, Takeover bid…
Bristol Myers: favorable opinion from the CHMP in anemia
(CercleFinance.com) – Bristol Myers Squibb announces that it has received a favorable opinion from the CHMP for Reblozyl (luspatercept) in the treatment of adults with transfusion anemia due to low…
Bristol Myers: Priority review accepted for Augtyro
Receive the value of the day for free every morning The data collected is essential for this processing and is intended for the relevant services of BFM Bourse and, where…
Bristol Myers: Expiration of the HSR period for RayzeBio
Receive the value of the day for free every morning The data collected is essential for this processing and is intended for the relevant services of BFM Bourse and, where…
Bristol Myers: 7% decline in EPS in the 4th quarter
(CercleFinance.com) – Bristol Myers Squibb publishes adjusted EPS (non-GAAP) for the last three months of 2023, down 7% to $1.70, for revenues up 1% to just under 11 .5 billion,…
Bristol Myers Squibb benefits from the success of its anemia products
(AOF) – Bristol Myers Squibb is expected to rise in pre-market on Wall Street after forgetting better than expected results for the fourth quarter. The American pharmaceutical group posted adjusted…
Bristol Myers: 2 FDA priority reviews for Breyanzi
(CercleFinance.com) – Bristol Myers Squibb indicates that health authorities have agreed to examine three regulatory applications relating to Breyanzi (lisocabtagene maraleucel): two applications have been accepted by the Food and…
Bristol Myers: positive trial for subcutaneous Opdivo
(CercleFinance.com) – Bristol Myers presented data this weekend from a phase 3 trial evaluating the subcutaneous formulation of Opdivo (nivolumab) versus intravenous (IV) Opdivo in patients with advanced or metastatic…
Bristol Myers: Positive trial for subcutaneous Opdivo
Receive the value of the day for free every morning The data collected is essential for this processing and is intended for the relevant services of BFM Bourse and, where…
Bristol Myers: received a positive opinion from the CHMP
(CercleFinance.com) – Bristol Myers Squibb receives a positive opinion from the CHMP for the CAR T cell therapy Abecma (idecabtagene vicleucel) in previous therapeutic lines for multiple myeloma exposed in…